for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BeiGene lung cancer treatment meets main goal in late-stage study

FILE PHOTO: People enter a building of biotechnology firm BeiGene Ltd at the Suzhou Industrial Park in Suzhou, Jiangsu province, China November 22, 2019. Picture taken November 22, 2019. REUTERS/Stringer

(Reuters) - BeiGene Ltd said on Tuesday its cancer therapy combination for treating lung cancer in previously untreated patients met the main goal in a late-stage study.

The therapy, tislelizumab, when administered in combination with chemotherapy helped reduce the risk of cancer progression in patients with squamous non-small cell lung cancer.

Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Shounak Dasgupta

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up